Global Autologous Stem Cell and Non-Stem Cell-Based Therapies Market - 2023-2030

Global Autologous Stem Cell and Non-Stem Cell-Based Therapies Market - 2023-2030

The Global Autologous Stem Cell and Non-Stem Cell-Based Therapies Market reached US$ 6.8 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 18.4 billion by 2030. The Global Autologous Stem Cell and Non-Stem Cell-Based Therapies Market is expected to exhibit a CAGR of 13.7% during the forecast period 2023-2030.

The growing number of chronic conditions, including neurodegenerative disorders, orthopedic injuries, and cardiovascular diseases, increasing demand for regenerative medicine, research advancements, and increase in market developments such as mergers, acquisitions, collaborations, product introductions, and approvals are among the fundamental elements expected to be promoting the global autologous stem cell and non-stem cell therapy based therapies market growth in the forecast period.

Market Dynamics

Increasing Research Activities on Autologous Stem Cell and Non-Stem Cell-Based Therapies Drive The Growth of Market

Increasing research activities are expected to boost global market growth in the forecast period. For instance, in June 2022, BlueRock Therapeutics, a leading engineered cell therapy corporation, finished registration in its open-label Phase 1 investigation that is aimed at assessing the safeness and primary effectiveness of its investigational cell-based therapy BRT-DA01 for progressive Parkinson’s condition. The therapy is developed to facilitate motor symptoms in Parkinson’s individuals who do not entirely respond to traditional drugs.

Moreover, in July 2022, Achilles Therapeutics, a biopharmaceutical corporation, announced that it has been awarded a USD 4.2 million grant designated ‘Horizon Europe’. It is the EU’s key grant initiative for investigation and innovation. This budget was awarded to promote personalized therapy manufacturing.

The Increasing Research Funding is Expected to Present the Global Autologous Stem Cell and Non-Stem Cell-Based Therapies Market With Growth Opportunities

The increasing research funding is presenting the global market with future growth opportunities. For instance, in July 2022, a corporation designing precision T cell therapies for the treatment of solid tumors reported that it is guiding a consortium that has been awarded a €4 million ($4.2 million) grant from Horizon Europe for the project titled Smart ManufactuRing for Autologous Cell ThERapies, facilitated by ingenious biomonitoring technologies and state-of-the-art procedure control and is expected to grow the advancements in cell therapy manufacturing procedures, by designing a first-in-class proof-of-concept “smart” bioprocessing manufacturing platform.

The High Cost Of Autologous Cell Therapy is Estimated To Hamper The Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market During The Forecast Period

The high cost of autologous cell therapy is hampering the growth of Global Autologous Stem Cell and Non-Stem Cell-Based Therapies in the forecast period. For instance, CAR T-cell therapy expense is estimated to be between US$500,000 and US$1,000,000.

COVID-19 Impact Analysis

The financial health of companies across all industries has been impacted by the COVID-19 pandemic and lockdown in numerous nations worldwide. Therefore, for the period of the COVID-19 public health emergency, the U.S. Food and Drug Administration (FDA) issued guidelines that include general considerations to aid sponsors and researchers, ensuring the safety of trial participants, adhering to good clinical practice (GCP), and minimizing risks to trial integrity.

Russia-Ukraine War Impact Analysis

The Russia-Ukraine brawl is considered to carry very little impact on the global autologous stem cell and non-stem cell-based therapies market, as the low prevalence and dearth of critical market players in this region. Yet, persisting to countenance raids from Russian troops, Ukrainian infirmaries are pushed by increasing numerals of deaths and specified medical aids. There are deficiencies across all kinds of drugs.

Again, the consequence of the import and export of basic materials is predicted to have a small influence on the growth of global autologous stem cell and non-stem cell-based therapies in the forecast period.

Segment Analysis

The Global Autologous Stem Cell and Non-Stem Cell-Based Therapies Market is segmented based on type, application, end-user, and region.

The Cancer Application is Estimated to Dominate the Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market

Owing to the increasing product approval for cancer applications, the cancer application of autologous stem cell and non-stem cell-based therapies is estimated to dominate the global market holding around 39.7%. For instance, in May 2022, Novartis, a multinational healthcare corporation, obtained US FDA clearance for Kymriah CAR-T cell therapy for adults with relapsed or refractory follicular lymphoma. Also, in February 2022, the US FDA authorized CARVYKTI (ciltacabtagene autoleucel; cilta-cel) to treat adults with relapsed or refractory multiple myeloma (RRMM) after four or more additional previous lines of treatment. CARVYKTI is a B-cell maturation antigen-directed, genetically altered autologous T-cell immunotherapy.

Geographical Analysis

Europe is Estimated to Hold 27.3% of the Market Share Owing to the Growing Cases of Chronic Conditions in this Region.

Owing to the increasing cases of chronic conditions, including cardiovascular disorders, neurological disorders, and cancer, in Europe, the region is estimated to hold the second-largest share of the global market, accounting for about 27.3% of the total market share by 2030. For instance, according to the Joint Research Centre estimates, there were around four million fresh cancer diagnoses in Europe in 2020 and almost 1.9 million individuals were estimated to have died from cancer in 2020.

Also, according to the UK Parliament, almost one out of six individuals in the UK hold at least one neurological disorder, with an estimated 600,000 individuals diagnosed annually, they can affect anyone at any time. Also, according to the NHS, CVD impacts about seven million individuals in the UK and is a substantial reason for disability and death and CVD is accountable for one in four early deaths in the UK and accounts for the biggest void in health life longing.

Competitive Landscape

The major global players in the autologous stem cell and non-stem cell-based therapies market include Novartis AG, BrainStorm Cell Limited, Caladrius, Cytori Therapeutics Inc., Gilead Sciences Inc., Regeneus Ltd, U.S. Stem Cell, Vericel Corporation, MEDIPOST, Castle Creek Biosciences, Inc., among others.

Why Purchase the Report?
• To visualize the Global Autologous Stem Cell and Non-Stem Cell-Based Therapies Market segmentation based on type, application, end-user, and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of autologous stem cell and non-stem cell-based therapies market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Type mapping available in Excel consisting of key types of all the major players.

The Global Autologous Stem Cell And Non-Stem Cell-Based Therapies Market Report Would Provide Approximately 53 Tables, 54 Figures And 195 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies